来自MSN

REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug

・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...